Cours suspendu

Autres langues Sonnet Biotherapeutics

Actions

SONN

US83548R4020

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 02/12/2025			Varia. 5j.	Varia. 1 janv.
1,260 ^USD	-59,35 %		-.--%	-

16/12	Sonnet BioTherapeutics Holdings, Inc. publie ses résultats financiers pour l'exercice clos le 30 septembre 2025	CI
02/12	Forte baisse à la mi-journée pour Sonnet BioTherapeutics, Janux Therapeutics et Health In Tech	MT

Autres langues

16/12	Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025
02/12	Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
02/12	Top Midday Decliners
02/12	Sonnet Biotherapeutics Holdings announces stockholder approval of proposed business combination with Hyperliquid Strategies
02/12	Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
02/12	Sonnet BioTherapeutics Holdings, Inc.(NasdaqCM:SONN) dropped from NASDAQ Composite Index
02/12	Hyperliquid Strategies Inc completed the acquisition of Sonnet BioTherapeutics Holdings, Inc. in a reverse merger transaction.
18/11	Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting
15/10/25	Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma
15/10/25	Sonnet BioTherapeutics Holdings, Inc. Collaborates with Spanishos on Non-Clinical Study Using New Alternate Methodologies Based Patient-Derived Tumoroid Platform
19/09/25	Sonnet to Present at the MedInvest Biotech & Pharma Conference
15/09/25	Top Premarket Decliners
13/08/25	Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2025
12/08/25	Sonnet Releases Virtual Investor What This Means Segment
11/08/25	Sonnet Releases Virtual Investor "What This Means" Segment
11/08/25	Sonnet BioTherapeutics Holdings, Inc. Announces Expansion of Its Clinical Study of Patients with Platinum-Resistant Ovarian Cancer
04/08/25	Sonnet BioTherapeutics Expanding Ovarian Cancer Drug Study
04/08/25	Sonnet Biotherapeutics expands trial of SON-1010 with atezolizumab in advanced ovarian cancer
04/08/25	Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
04/08/25	Sonnet BioTherapeutics Holdings, Inc. Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
15/07/25	Top Premarket Decliners
14/07/25	Top Midday Gainers
14/07/25	Traders Digest Tariff Announcements, Driving Premarket Losses for US Equity Futures
14/07/25	Top Premarket Gainers
14/07/25	Sonnet Biotherapeutics, Inc Announces $888 Million Business Combination with Rorschach I LLC to Create Entity to Be Named Hyperliquid Strategies Inc